UTHR Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
783.3M
+0.2%
781.5M
-1.1%
790.2M
-1.2%
799.5M
+0.1%
798.6M
Cost of Revenue
99.5M
-25.4%
133.4M
+29.0%
103.4M
+2.5%
100.9M
+15.2%
87.6M
Gross Profit
683.8M
+5.5%
648.1M
-5.6%
686.8M
-1.7%
698.6M
-1.7%
711.0M
Operating Expenses
353.0M
+9.5%
322.3M
-2.4%
330.1M
+6.4%
310.1M
-10.5%
346.5M
R&D
146.3M
+5.9%
138.2M
-0.9%
139.5M
+9.4%
127.5M
-4.9%
134.0M
SG&A
206.7M
+12.3%
184.1M
-3.4%
190.6M
+4.4%
182.6M
-14.1%
212.5M
Operating Income
330.8M
+1.5%
325.8M
-8.7%
356.7M
-8.2%
388.5M
+6.6%
364.5M
EBITDA
355.0M
+1.9%
348.4M
-8.2%
379.5M
-7.5%
410.4M
+6.4%
385.6M
Net Income
333.0M
+21.1%
274.9M
-24.5%
364.3M
+7.6%
338.7M
+9.4%
309.5M
EPS (Basic)
$7.82
+23.7%
$6.32
-24.7%
$8.39
+8.5%
$7.73
+12.7%
$6.86
EPS (Diluted)
$7.27
+24.9%
$5.82
-24.3%
$7.69
+7.4%
$7.16
+11.7%
$6.41
Shares (Diluted)
45.8M
-3.0%
47.2M
-0.4%
47.4M
+0.2%
47.3M
-2.1%
48.3M
United Therapeutics (UTHR) โ€” Financials